Healthcare
Tempus AI, Inc.(TEM)
Live Price
Offline$47.82
-3.57% today
1Y Change
-23.41%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $9.59B
- Revenue Growth
- +83.4%
- EPS Growth
- +69.3%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tempus AI, Inc. (TEM) is a Healthcare stock with a market cap of $9.59B and listed on NASDAQ. The stock last traded around $47.82 and down 23.4% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +83.4%, EPS growth of +69.3%, a dividend yield of 0.0%. What stands out right now is revenue +83.4%, EPS +69.3%, free cash flow -13.2% with operating margin -18.8% and ROIC -10.3%. Valuation sits in the middle of the pack at price/sales 7.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TEM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+83.4% vs +7.6% peer median
Operating Margin
Below sector median
-18.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +83.4% and EPS at +69.3%, with operating margin around -18.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -13.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -1.1% | -13.2% | -12.1% |
2026 Feb 24, 2026 | +8.8% | -7.3% | -11.3% | -15.7% |
2025 Nov 4, 2025 | +36.1% | -2.6% | -15.3% | -11.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TEM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TEM Max Drawdown
-58.96%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TEM and SPY.
Company Overview
Tempus AI, Inc.
NASDAQ Global Select
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
- Leadership
- Eric Lefkofsky
- IPO Date
- Jun 14, 2024
- Employees
- 2.4k
- Street Address
- 600 West Chicago Avenue
- Mailing
- Chicago, IL, 60654
- Region
- Chicago, IL, US
- Reporting Currency
- USD
- Investor Line
- 800 976 5448
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 7.5
- Price/Book
- 19.5
Growth
- Revenue
- +83.4%
- EPS
- +69.3%
- Free Cash Flow
- -13.2%
Profitability
- Gross Margin
- 69.6%
- Operating Margin
- -18.8%
- Net Margin
- -19.3%
- ROE
- -59.9%
- ROIC
- -10.3%
Balance Sheet
- Debt/Equity
- 1.66
- Current Ratio
- 3.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.